As a result, Moderna's shares have suffered, falling more than 90% since their peak in 2021. Now let's consider where Moderna will be a few years from now. The company recently said it aims to ...

The exhibition Pink Sails highlights some of the imagery and styles that existed side by side in an era of major social change.

Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires ...

Moderna stock hasn’t been a favorite of investors since demand for its coronavirus vaccine started to drop. But this biotech is showing the market that it has what it takes to produce multiple ...

In the exhibition, the audience will encounter about a hundred works by Swedish and international artists with drawing as the lowest common denominator. In Abuse Is the Beauty of the Working Class, ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an earnings perspective. As one of the leading coronavirus vaccine companies ...

One of the largest biotech companies in the country has filed a lawsuit claiming improper building practices led to millions in damages at one of its new manufacturing facilities. Moderna is ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that focuses on developing messenger RNA (mRNA) medicines and vaccines.

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and ...

The rivalry between Moderna and Pfizer/BioNTech in commercialising their COVID-19 vaccines has now spilled over into the courts, in the form of a patent infringement lawsuit.